AccuStem Sciences, Inc.

AI-generated fair value estimate for this company.

Method: Net cash/asset basis: cash and short-term investments of ~$0.01M against total debt of ~$0.06M as of 6/30/2026 (TTM), a slightly negative net cash position, across ~16.08M shares (implied by $1.93M market cap / $0.12 price); per-share value floored at $0.00.

Reasoning: AccuStem Sciences is an early-stage cancer-diagnostics spin-off with no meaningful product revenue and a near-zero balance sheet, so there are no cash flows to discount; a cash/net-asset basis is the only defensible real-calculation method, and it indicates no fundamental equity value beyond the company's diagnostic IP optionality, which cannot yet be reliably monetized or valued.